Navigation Links
Genetics contribute to increased risk for end-stage renal disease for African Americans with CKD
Date:11/26/2013

WASHINGTON (Nov. 26, 2013) In the United States, African Americans have approximately twice the risk of end-stage renal disease compared to white Americans, despite a similar prevalence in earlier stages of chronic kidney disease. A large study co-authored by George Washington University (GW) researcher Dominic Raj, M.D., identifies factors that mediate differences in the progression of chronic kidney disease between black patients and white patients, as well as among black patients, in order to reduce the excess burden of end-stage renal disease and its complications in black patients.

The findings, published in the New England Journal of Medicine, examines the effects of variants in the gene encoding apolipoprotein L1 (APOL1) on the progression of chronic kidney disease, according to whether patients have two copies of high-risk APOL1 variants (APOL1 high-risk group) or zero or one copy (APOL1 low-risk group). Renal risk variants in APOL1 were associated with higher rates of end-stage renal disease and progression of chronic kidney disease that were observed in black patients as compared with white patients, regardless of diabetes status.

The findings came from two large National Institutes of Health-funded study cohorts of nearly 5,000 individuals with kidney disease, including the African American Study of Kidney Disease and Hypertension (AASK) and the Chronic Renal Insufficiency Cohort (CRIC) study. The study was supported, in part, by a recent R0-1 grant awarded to Raj.

"This study is a unique example of the importance of collaboration across institutions to deliver high quality science," said Raj, director of the division of nephrology and professor of medicine at the GW School of Medicine and Health Sciences.

The AASK study, which enrolled African American patients with chronic kidney disease attributed to hypertension, found that kidney failure occurred in 58.1 percent of patients in the APOL1 high-risk group and 36.6 percent of those in the APOL1 low-risk group. In the CRIC study, kidney function decline was greater among black patients in the APOL1 high-risk group, but it was similar among black patients in the APOL1 low-risk group and white patients, regardless of their diabetes status.

"This study shows that APOL1 variant confers risk for progression of kidney diseases, independent of blood pressure control and diabetic status in African Americans. Chronic kidney disease is one of the most glaring examples of racial and ethnic disparities in health outcomes in the United States," said Raj. "While this is an important contribution that furthers our understanding for the cause for such disparity, this study also highlights the need for further studies that could lead to risk stratification and early and targeted interventions."


'/>"/>

Contact: Lisa Anderson
lisama2@gwu.edu
202-994-3121
George Washington University
Source:Eurekalert

Related biology news :

1. Babcock Genetics Launches Breed Select Program
2. Genetics in Medicine publishes special issue dedicated to genomics in electronic health records
3. Genetics Society of America joins editorial partnership for CBE-Life Sciences Education
4. Genetics society and cell biologists partner for life sciences education journal
5. Researchers untangle genetics of drug resistant TB
6. Unscrambling the genetics of the chickens blue egg
7. European Society of Human Genetics urges caution over use of new genetic sequencing techniques
8. Genetics Society of Americas GENETICS journal highlights for May 2013
9. Genetics defines a distinct liver disease
10. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
11. Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we ... of recovery so we need to do it well. Inadequate sleep levels have been ... blood pressure, stroke, diabetes, and even cancer. Maybe now is the best ... that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 2016 Oxford Gene Technology ... NGS panel range with the launch of the SureSeq myPanel™ ... of variants in familial hypercholesterolemia (FH). The panel delivers single ... a single small panel and allows customisation by ,mix and ... exons for LDLR , P C ...
(Date:12/8/2016)... Worcester, Mass (PRWEB) , ... December 08, 2016 ... ... KbioBox genetic data bioInformatics portal. In response to client demand KbioBox developed a ... gene edit biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... Francisco, CA (PRWEB) , ... December 08, 2016 ... ... Oculus as finalists in the World Technology Awards. uBiome is one of just ... received across all categories. , In addition to uBiome, companies nominated as finalists ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
Breaking Biology Technology: